



TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL QUARTER ENDED
30 SEPTEMBER 2025**

Contact

Level 11, No.11, Jalan Teknologi,
Taman Sains Selangor 1, PJU 5,
Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

www.tmclife.com

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2025

	3 months ended	
	Current Year To Date 30/09/2025 RM'000	Preceding Year Corresponding Period 30/09/2024 RM'000
Revenue	100,477	81,967
Other operating income	1,796	879
Inventories and consumables	(36,710)	(26,205)
Staff costs	(29,208)	(28,794)
Other operating expenses	(19,072)	(15,084)
Depreciation and amortisation	(9,347)	(7,226)
Interest income	680	1,340
Finance costs	(2,049)	(2,418)
Profit before taxation	6,567	4,459
Taxation	(2,154)	(1,523)
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	4,413	2,936
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period attributable to:-		
Owners of the parent	4,413	2,936
Profit per ordinary share attributable to the owners of the parent (sen)		
Basic/diluted	0.25	0.17

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2025

	Attributable to owners of the parent			Total equity RM'000
	Share capital RM'000	Non-distributable	Distributable	
		Share options reserve RM'000	Retained profits RM'000	
Balance at 1 July 2025	625,986	-	227,057	853,043
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	-	-	4,413	4,413
Balance at 30 September 2025	625,986	-	231,470	857,456
Balance at 1 July 2024	625,986	1,316	260,732	888,034
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	3,606	3,606
Transactions with owners				
Share options granted under ESOS	-	19	-	19
Transfer within reserve for ESOS forfeited	-	(1,335)	1,335	-
Dividend paid	-	-	(38,616)	(38,616)
Total transactions with owners	-	(1,316)	(37,281)	(38,597)
Balance at 30 June 2025	625,986	-	227,057	853,043

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2025

	As At 30/09/2025 Unaudited RM'000	As At 30/06/2025 Audited RM'000
Non-current assets		
Property, plant and equipment	721,103	725,778
Intangible assets	200,077	201,192
Investment property	2,025	2,039
Deferred tax assets	701	700
Total non-current assets	923,906	929,709
Current assets		
Inventories	16,631	15,908
Trade and other receivables	65,372	65,600
Tax recoverable	10,346	11,409
Cash and bank balances	110,845	109,564
Total current assets	203,194	202,481
TOTAL ASSETS	1,127,100	1,132,190
Current liabilities		
Contract liabilities	508	519
Trade and other payables	65,449	69,286
Borrowings	41,578	38,047
Lease liabilities	2,047	1,901
Income tax payable	67	559
Total current liabilities	109,649	110,312
NET CURRENT ASSETS	93,545	92,169
Non-current liabilities		
Contract liabilities	336	357
Borrowings	130,203	141,426
Lease liabilities	2,016	1,598
Provision	753	739
Deferred tax liabilities	26,687	24,715
Total non-current liabilities	159,995	168,835
TOTAL LIABILITIES	269,644	279,147
NET ASSETS	857,456	853,043
Represented by:		
Equity attributable to owners of the parent		
Share capital	625,986	625,986
Retained profits	231,470	227,057
TOTAL EQUITY	857,456	853,043
Net assets per share (RM)	0.49	0.49

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2025

	Current Year To Date 30/09/2025 RM'000	Preceding Year Corresponding Period 30/09/2024 RM'000
Cash flows from operating activities		
Profit before tax	6,567	4,459
Adjustments for :-		
Non-cash items	9,593	7,472
Interest expense	2,049	2,418
Interest income	(680)	(1,340)
Operating profit before changes in working capital	17,529	13,009
Changes in working capital		
Net change in current assets	(729)	(4,217)
Net change in trade and other payables and contract liabilities	(3,871)	(5,759)
Cash generated from operations	12,929	3,033
Interest paid	(1,991)	(2,384)
Net income tax paid	389	(721)
Net cash flows generated from operating activities	11,327	(72)
Cash flows used in investing activities		
Acquisition of property, plant and equipment	(1,745)	(12,464)
Acquisition of intangible assets	(596)	(405)
Proceeds from disposal of property, plant and equipment	3	-
Withdrawal/(Placement) of deposits placed with:-		
- financial institutions with original maturity of more than three (3) months	16,024	(521)
- deposits pledged	90	210
Interest received	680	1,340
Net cash flows generated used in investing activities	14,456	(11,840)
Cash flows used in financing activities		
Payment of lease liabilities	(641)	(570)
Repayment of term loans	(7,527)	(3,775)
Repayment of hire purchase	(221)	(220)
Net cash flows used in financing activities	(8,389)	(4,565)
Net increase/(decrease) in cash & cash equivalents	17,394	(16,477)
Cash & cash equivalents at beginning of the financial period	60,822	107,511
Cash & cash equivalents at end of the financial period	78,216	91,034
Cash & cash equivalents at end of the financial period		
Cash at banks and on hand	46,092	38,126
Deposits with licenced banks	64,753	134,280
	110,845	172,406
Less: Deposits with licensed banks (for more than 3 months)	(28,613)	(77,382)
Deposit pledged to a licenced bank	(1,556)	(1,530)
Cash restricted in use	(2,460)	(2,460)
	78,216	91,034

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2025**

**A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING
STANDARDS (“MFRS”)**

A1 BASIS OF PREPARATION

The interim financial report is audited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2025. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2025, and changes in financial performance since the preceeding year corresponding period.

The accounting policies and methods of computations used in the preparation of the financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2025, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2025 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the financial statements of the Group.

A2 SEASONALITY OR CYCLICALITY OF OPERATIONS

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A4 CHANGE IN ACCOUNTING ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial quarter under review.

A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

A6 DIVIDEND PAID

No dividend was paid during the financial period ended 30 September 2025.

A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 30 September 2025 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

Financial guarantees

	30/09/2025	30/06/2025
	RM'000	RM'000
<u>Unsecured</u>		
Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries	171,781	179,473
Letter of guarantee given to suppliers	5,270	9,225
	<u>177,051</u>	<u>188,698</u>

A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure is as follows:

	30/09/2025	30/06/2025
	RM'000	RM'000
Approved and contracted for	<u>28,106</u>	<u>29,581</u>

A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2025**

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter (3 months ended 30 September 2025 versus 3 months ended 30 September 2024)

	3 months ended	
	30/09/2025	30/09/2024
	RM'000	RM'000
Revenue	100,477	81,967
Profit before taxation	6,567	4,459

For the quarter ended 30 September 2025, the Group recorded revenue of RM100.5 million and profit before taxation of RM6.6 million, representing an increase of 23% and 47% respectively, compared to the previous corresponding quarter. The increase in profit before taxation was due to contribution from our various specialty including Oncology and reduced discount to corporate customers at Thomson Hospital Kota Damansara ("THKD").

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

**B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER
(3 months ended 30 September 2025 versus 3 months ended 30 June 2025)**

	3 months ended	
	30/09/2025	30/06/2025
	RM'000	RM'000
Revenue	100,477	93,273
Profit before taxation	6,567	3,054

The Group recorded an 8% increase in revenue and more than double in profit before taxation compared to the previous quarter ended 30 June 2025, supported by higher patient volumes across all admission categories.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2026

Global economic uncertainties arising from rising tariffs and trade restrictions continue to affect various industries. These challenges may lead to higher costs of medical supplies and occasional supply chain disruptions. While the Group has not experienced any material impact to date, it continues to monitor supply chain developments closely to ensure operational resilience and business sustainability.

Despite the external headwinds faced by the healthcare industry, the Group remains optimistic about its growth trajectory. Growth is expected to be driven by the increased capacity at THKD and the ongoing expansion across specialties. The Group is also focusing on diversifying its customer base to attract more corporate and international patients, while strengthening partnerships with insurers to sustain long-term business growth.

Building on this momentum, the Group continues to execute strategic initiatives to enhance operational efficiency, optimise costs, and expand its market reach. These efforts underscore Management's commitment to driving sustainable growth and improving profitability through disciplined execution.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

There is no profit forecast or profit guarantee for the financial period ended 30 September 2025.

B5 TAXATION

	Individual quarter	
	30/09/2025	30/09/2024
	RM'000	RM'000
In respect of current quarter / financial period		
Current tax expense	182	604
Deferred tax expense	1,972	919
	<u>2,154</u>	<u>1,523</u>

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

B6 STATUS OF CORPORATE PROPOSAL

There are no corporate proposals announced but not completed as at 20 November 2025, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

B7 BORROWINGS

The Group's borrowings are as follows:-

	Long Term	Short Term	Total
	RM'000	RM'000	RM'000
As at 30 September 2025			
Secured - Denominated in Ringgit Malaysia	<u>130,203</u>	<u>41,578</u>	<u>171,781</u>
As at 30 June 2025			
Secured - Denominated in Ringgit Malaysia	<u>141,426</u>	<u>38,047</u>	<u>179,473</u>

Included in borrowings of the Group is an amount of Industrial Hire Purchase of RM221,000 (30 June 2025: RM442,000).

B8 MATERIAL LITIGATION

There was no material litigation as at the date of this report.

B9 DIVIDENDS

The Board does not recommend any dividend for the current quarter under review (previous year corresponding period ended 30 September 2024: NIL)

B10 EARNINGS PER SHARE (EPS)

	Individual quarter	
	30/09/2025	30/09/2024
Basic EPS		
Net profit attributable to owners of the parent (RM'000)	4,413	2,936
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882
EPS (sen) - Basic	0.25	0.17

B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter	
	30/09/2025	30/09/2024
	RM'000	RM'000
Interest income	680	1,340
Interest expense	(2,047)	(2,414)
Unwinding of discount on provision for restoration	(2)	(4)
Depreciation of property, plant and equipment, investment property and right-of-use assets	(7,637)	(6,492)
Amortisation of intangible assets	(1,710)	(734)
Impairment loss on receivables	(210)	(210)
Fair value charges on share options granted under ESOS	-	(5)
Property, plant and equipment written off	(16)	(4)
Gain on disposal of property, plant and equipment	3	-
Inventories written off	(23)	(27)

B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 30 September 2025 and 30 June 2025.

B14 AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 27 November 2025.